Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Operating Expenses (2021 - 2025)

Amylyx Pharmaceuticals has reported Operating Expenses over the past 5 years, most recently at $36.6 million for Q4 2025.

  • Quarterly results put Operating Expenses at $36.6 million for Q4 2025, down 8.46% from a year ago — trailing twelve months through Dec 2025 was $153.3 million (down 61.88% YoY), and the annual figure for FY2025 was $153.3 million, down 61.88%.
  • Operating Expenses for Q4 2025 was $36.6 million at Amylyx Pharmaceuticals, up from $36.0 million in the prior quarter.
  • Over the last five years, Operating Expenses for AMLX hit a ceiling of $210.8 million in Q1 2024 and a floor of $12.9 million in Q1 2021.
  • Median Operating Expenses over the past 5 years was $51.0 million (2022), compared with a mean of $60.2 million.
  • Biggest five-year swings in Operating Expenses: soared 271.57% in 2022 and later plummeted 82.06% in 2025.
  • Amylyx Pharmaceuticals' Operating Expenses stood at $28.3 million in 2021, then surged by 134.78% to $66.5 million in 2022, then surged by 60.23% to $106.5 million in 2023, then crashed by 62.46% to $40.0 million in 2024, then fell by 8.46% to $36.6 million in 2025.
  • The last three reported values for Operating Expenses were $36.6 million (Q4 2025), $36.0 million (Q3 2025), and $42.9 million (Q2 2025) per Business Quant data.